| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Eliem Therapeutics, Inc. | COO & CFO | Stock Option (Right to Buy) | 170,000 | 31 Oct 2022 | Direct | ||
| Neoleukin Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 25,000 | 08 Jun 2023 | Direct | ||
| Aerovate Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 23,017 | 29 Apr 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| JBIO | Jade Biosciences, Inc. | 29 Apr 2025 | 1 | $0 | 4 | Director | 01 May 2025, 18:15 |
| JBIO | Jade Biosciences, Inc. | 28 Apr 2025 | 0 | $0 | 3 | Director | 01 May 2025, 17:51 |
| NGNE | Neoleukin Therapeutics, Inc. | 08 Jun 2023 | 1 | $0 | 4 | Director | 09 Jun 2023, 16:25 |
| CLYM | Eliem Therapeutics, Inc. | 31 Oct 2022 | 1 | $0 | 4 | COO & CFO | 02 Nov 2022, 19:08 |
| NGNE | Neoleukin Therapeutics, Inc. | 12 May 2022 | 1 | $0 | 4 | Director | 16 May 2022, 18:23 |
| CLYM | Eliem Therapeutics, Inc. | 27 Jan 2022 | 1 | $0 | 4 | COO & CFO | 31 Jan 2022, 16:16 |
| CLYM | Eliem Therapeutics, Inc. | 09 Aug 2021 | 0 | $0 | 3 | COO & CFO | 09 Aug 2021, 18:11 |